Literature DB >> 6981286

Neutrophil and lymphocyte function in patients with diabetes mellitus.

N H Valerius, C Eff, N E Hansen, H Karle, J Nerup, B Søeberg, S F Sørensen.   

Abstract

Neutrophil granulocyte chemotaxis and intraneutrophilic and plasma levels of lysozyme as well as the number of T and B lymphocytes and lymphocyte transformation in vitro on stimulation with mitogens and microbial antigens were studied in four groups of patients with diabetes mellitus (DM). Twelve patients with insulin-dependent diabetes mellitus (IDDM) and ketoacidosis and 4 patients with non-insulin-dependent diabetes mellitus were studied at the time of diagnosis and before and after start of treatment. Ten patients with IDDM of less than 10 years' duration which had been difficult to regulate well and 10 patients with IDDM well regulated for more than 20 years were studied at their regular outpatient visits. Apart from a slight increase in plasma lysozyme in group 1 from the first to the second examination, we found no differences between diabetics and healthy control persons. It is concluded that if patients with DM are more susceptible to infections, it is probably caused by elements of neutrophil or lymphocyte function not examined in this study or by factors unrelated to immunity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981286     DOI: 10.1111/j.0954-6820.1982.tb01983.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  25 in total

1.  Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome.

Authors:  T Benfield; J S Jensen; B G Nordestgaard
Journal:  Diabetologia       Date:  2006-12-23       Impact factor: 10.122

2.  Bactericidal proteins and neutral proteases in diabetes neutrophils.

Authors:  G Oberg; R Hällgren; L Moberg; P Venge
Journal:  Diabetologia       Date:  1986-07       Impact factor: 10.122

3.  Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United States.

Authors:  Lindsey Korbel; John David Spencer
Journal:  J Diabetes Complications       Date:  2014-11-25       Impact factor: 2.852

4.  Pneumomediastinum as a complication of emphysematous cholecystitis: case report.

Authors:  Luciano Delgado-Plasencia; Ignacio González-García; Diana Rodríguez-González; Esther Torres-Monzón A
Journal:  BMC Gastroenterol       Date:  2010-09-02       Impact factor: 3.067

5.  Significant asymptomatic bacteriuria among Nigerian type 2 diabetics.

Authors:  C O Alebiosu; O A Osinupebi; F A Olajubu
Journal:  J Natl Med Assoc       Date:  2003-05       Impact factor: 1.798

6.  Comparative study of emphysematous pyelonephritis and pyelonephritis in type 2 diabetes: a single-centre experience.

Authors:  Tauseef Nabi; Nadeema Rafiq; Mohammad Hifz Ur Rahman; Shahnawaz Rasool; Nayeem U Din Wani
Journal:  J Diabetes Metab Disord       Date:  2020-09-28

Review 7.  The impact of diabetes on the pathogenesis of sepsis.

Authors:  G C K W Koh; S J Peacock; T van der Poll; W J Wiersinga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

8.  Ambient PM2.5 exposure up-regulates the expression of costimulatory receptors on circulating monocytes in diabetic individuals.

Authors:  Alexandra Schneider; Neil E Alexis; David Diaz-Sanchez; Lucas M Neas; Shirley Harder; Margaret C Herbst; Wayne E Cascio; John B Buse; Annette Peters; Robert B Devlin
Journal:  Environ Health Perspect       Date:  2010-12-17       Impact factor: 9.031

9.  Association Between Antihypertensive Use and Hospitalized Pneumonia in Patients With Stroke: A Korean Nationwide Population-Based Cohort Study.

Authors:  Jae-Hyun Yun; Seung Yeon Rhee; Sungyoun Chun; Hyoung Seop Kim; Byung-Mo Oh
Journal:  J Korean Med Sci       Date:  2022-04-18       Impact factor: 5.354

10.  Glucose transport in human peripheral blood lymphocytes influenced by type 2 diabetes mellitus.

Authors:  Paweł Piatkiewicz; Anna Czech; Jan Tatoń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-03-20       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.